Tyra Biosciences (NASDAQ:TYRA) Earns Buy Rating from HC Wainwright

Tyra Biosciences (NASDAQ:TYRA)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $30.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 244.04% from the stock’s previous close.

A number of other analysts have also recently weighed in on TYRA. UBS Group assumed coverage on Tyra Biosciences in a research report on Tuesday, January 7th. They set a “buy” rating and a $28.00 price objective for the company. Wedbush restated an “outperform” rating and set a $30.00 price target on shares of Tyra Biosciences in a research note on Friday, March 28th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $30.83.

Tyra Biosciences Stock Down 6.2 %

TYRA opened at $8.72 on Monday. Tyra Biosciences has a 52 week low of $8.66 and a 52 week high of $29.60. The business’s 50 day moving average is $12.18 and its two-hundred day moving average is $16.13. The firm has a market cap of $441.26 million, a price-to-earnings ratio of -5.42 and a beta of 1.09.

Tyra Biosciences (NASDAQ:TYRA) last announced its earnings results on Thursday, March 27th. The company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.05. Equities analysts expect that Tyra Biosciences will post -1.57 EPS for the current fiscal year.

Insider Transactions at Tyra Biosciences

In other Tyra Biosciences news, Director Nina S. Kjellson sold 3,993 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $16.36, for a total transaction of $65,325.48. Following the transaction, the director now owns 3,707,420 shares of the company’s stock, valued at $60,653,391.20. This represents a 0.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders sold a total of 21,998 shares of company stock worth $344,818 over the last ninety days. 15.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of TYRA. Rhumbline Advisers boosted its position in shares of Tyra Biosciences by 4.1% in the fourth quarter. Rhumbline Advisers now owns 26,202 shares of the company’s stock worth $364,000 after acquiring an additional 1,027 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in Tyra Biosciences during the fourth quarter worth approximately $31,000. Bank of New York Mellon Corp grew its stake in shares of Tyra Biosciences by 5.2% during the 4th quarter. Bank of New York Mellon Corp now owns 45,007 shares of the company’s stock valued at $626,000 after buying an additional 2,221 shares during the period. Wells Fargo & Company MN increased its holdings in shares of Tyra Biosciences by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 9,493 shares of the company’s stock worth $132,000 after buying an additional 3,236 shares during the last quarter. Finally, US Bancorp DE purchased a new position in shares of Tyra Biosciences in the 4th quarter worth $50,000. Institutional investors and hedge funds own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.